Cascadian Therapeutics completes follow-on

Cancer company Cascadian Therapeutics Inc. (NASDAQ:CASC) raised $82.5 million through the sale of 23.2 million shares at $3.30 and 1,818 shares of series E convertible preferred stock at $3,300 in co...